The Relationship between Low Serum Vitamin D Levels and Altered Intestinal Barrier Function in Patients with IBS Diarrhoea Undergoing a Long-Term Low-FODMAP Diet: Novel Observations from a Clinical Trial

Michele Linsalata, Giuseppe Riezzo, Antonella Orlando, Benedetta D'Attoma, Laura Prospero, Valeria Tutino, Maria Notarnicola, Francesco Russo, Michele Linsalata, Giuseppe Riezzo, Antonella Orlando, Benedetta D'Attoma, Laura Prospero, Valeria Tutino, Maria Notarnicola, Francesco Russo

Abstract

Decreased serum vitamin D (VD) levels have been associated with gastrointestinal (GI) disorders, including irritable bowel syndrome (IBS). VD can also modulate the intestinal barrier. Given the link between the GI barrier's alterations and diet, attention has aroused the positive effects of the Low FODMAP Diet (LFD) on IBS patients' symptom profile. We evaluated the GI symptoms and the urinary and circulating markers of GI barrier function, the markers of inflammation and intestinal dysbiosis in 36 IBS patients with predominant diarrhea (IBS-D) (5 men and 31 women, 43.1 ± 1.7 years) categorized for their circulating VD levels in low (L-VD) and normal (N-VD) (cutoff = 20 ng/mL). Evaluations were performed before and after 12 weeks of LFD. At the baseline, L-VD patients showed a significantly worse symptom profile and altered small intestinal permeability (s-IP) than N-VD. After LFD, a significant increase in the circulating VD levels in both the subgroups and a significant improvement of s-IP in L-VD patients occurred. Finally, VD levels negatively correlated with the symptom score and fecal zonulin. These data highlight the close relationship between VD and the intestinal barrier and support their involvement in IBS-D pathophysiology. Moreover, the potentially positive role of LFD in the management of IBS-D was confirmed.

Keywords: intestinal barrier; irritable bowel syndrome; low FODMAP diet; symptom profile; vitamin D.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The flow of participants through the study. IBS-D: irritable bowel syndrome with prevalent diarrhea. F: females. M: males.
Figure 2
Figure 2
VD levels in IBS-D patients as a whole group and categorized in L-VD and N-VD subgroups according to their low or normal vitamin D (VD) levels at baseline, before (pre) and after (post) 12 weeks of the low FODMAP diet. Data expressed as means ± SEM. Wilcoxon rank-sum test (solid line) was used to compare pre and post-treatment data. The Mann–Whitney test (dotted line) was applied in comparing the two subgroups before and at the end of the diet. Differences considered significant at p < 0.05. The red dotted line indicates the cutoff value.
Figure 3
Figure 3
Small intestinal permeability as evaluated by the sugar absorption test (panel (A) =% lactulose; panel (B) =% mannitol; panel (C) = La/Ma ratio; panel (D) =% sucrose) before (pre) and after (post) 12 weeks of low FODMAP diet in the IBS-D patients considered as a total group and categorized in L-VD and N-VD subgroups according to their low or normal VD levels at baseline. Data expressed as means ± SEM. Wilcoxon rank-sum test (solid line) was used to compare pre- and post-treatment data. The Mann–Whitney test (black dotted line) was applied in comparing the two subgroups before and at the end of the diet. Differences considered significant at p < 0.05. Red dotted line indicates the cutoff value of the La/Ma ratio (0.030).
Figure 4
Figure 4
Biomarkers of intestinal barrier function and integrity (panel (A) = fecal zonulin; panel (B) = serum zonulin, panel (C) = intestinal fatty acid-binding protein—I-FABP, and panel (D) = diamine oxidase—DAO) before (pre) and after (post) 12 weeks of low FODMAP diet in the IBS-D patients considered as a total group and categorized in L-VD and N-VD subgroups according to their low or normal VD levels at baseline. Data expressed as means ± SEM. Wilcoxon rank-sum test (solid line) was used to compare pre- and post-treatment data. The Mann–Whitney test (black dotted line) was applied in comparing the two subgroups before and at the end of the diet. Differences were considered significant at p < 0.05. Red dotted lines indicate the cutoff values for fecal and serum zonulin.
Figure 5
Figure 5
Indican (panel (A)) and skatole (panel (B)) levels as markers of dysbiosis before (pre) and after (post) 12 weeks of low FODMAP diet in the whole group of IBS-D patients and categorized in L-VD and N-VD subgroups according to their low or normal VD levels at baseline. Data expressed as means ± SEM. Wilcoxon rank-sum-test was used to compare pre- and post-treatment data. The Mann–Whitney test was applied in comparing the two subgroups before and at the end of the diet. Differences considered significant at p < 0.05. Red dotted lines indicate the cutoff value.

References

    1. Brett N.R., Lavery P., Agellon S., Vanstone C.A., Goruk S., Field C.J., Weiler H.A. Vitamin D Status and Immune Health Outcomes in a Cross-Sectional Study and a Randomized Trial of Healthy Young Children. Nutrients. 2018;10:680. doi: 10.3390/nu10060680.
    1. Sassi F., Tamone C., D’Amelio P. Vitamin D: Nutrient, Hormone, and Immunomodulator. Nutrients. 2018;10:1656. doi: 10.3390/nu10111656.
    1. Panarese A., Pesce F., Porcelli P., Riezzo G., Iacovazzi P.A., Leone C.M., De Carne M., Rinaldi C.M., Shahini E. Chronic functional constipation is strongly linked to vitamin D deficiency. World J. Gastroenterol. 2019;25:1729–1740. doi: 10.3748/wjg.v25.i14.1729.
    1. Tazzyman S., Richards N., Trueman A.R., Evans A.L., Grant V.A., Garaiova I., Plummer S.F., Williams E.A., Corfe B.M. Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: Outcomes from a pilot trial. BMJ Open Gastroenterol. 2015;2:e000052. doi: 10.1136/bmjgast-2015-000052.
    1. Abbasnezhad A., Amani R., Hajiani E., Alavinejad P., Cheraghian B., Ghadiri A. Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: A randomized double-blind clinical trial. Neurogastroenterol. Motil. 2016;28:1533–1544. doi: 10.1111/nmo.12851.
    1. Gil A., Plaza-Diaz J., Mesa M.D. Vitamin D: Classic and Novel Actions. Ann. Nutr. Metab. 2018;72:87–95. doi: 10.1159/000486536.
    1. Williams C.E., Williams E.A., Corfe B.M. Vitamin D status in irritable bowel syndrome and the impact of supplementation on symptoms: What do we know and what do we need to know? Eur. J. Clin. Nutr. 2018;72:1358–1363. doi: 10.1038/s41430-017-0064-z.
    1. Katrinaki M., Kampa M., Margioris A., Castanas E., Malliaraki N. Vitamin D levels in a large Mediterranean cohort: Reconsidering normal cut-off values. Hormones (Athens) 2016;15:205–223. doi: 10.14310/horm.2002.1674.
    1. Khalighi Sikaroudi M., Mokhtare M., Janani L., Faghihi Kashani A.H., Masoodi M., Agah S., Abbaspour N., Dehnad A., Shidfar F. Vitamin d3 supplementation in diarrhea-predominant irritable bowel syndrome patients: The effects on symptoms improvement, serum corticotropin-releasing hormone, and interleukin-6—A randomized clinical trial. Complementary Med. Res. 2020;27:302–309. doi: 10.1159/000506149.
    1. Silva M.C., Furlanetto T.W. Intestinal absorption of vitamin D: A systematic review. Nutr. Rev. 2018;76:60–76. doi: 10.1093/nutrit/nux034.
    1. Assa A., Vong L., Pinnell L.J., Avitzur N., Johnson-Henry K.C., Sherman P.M. Vitamin d deficiency promotes epithelial barrier dysfunction and intestinal inflammation. J. Infect. Dis. 2014;210:1296–1305. doi: 10.1093/infdis/jiu235.
    1. Fakhoury H.M.A., Kvietys P.R., Al Kattan W., Anouti F.A., Elahi M.A., Karras S.N., Grant W.B. Vitamin D and intestinal homeostasis: Barrier, microbiota, and immune modulation. J. Steroid Biochem. Mol. Biol. 2020;200:105663. doi: 10.1016/j.jsbmb.2020.105663.
    1. Akimbekov N.S., Digel I., Sherelkhan D.K., Lutfor A.B., Razzaque M.S. Vitamin D and the Host-Gut Microbiome: A Brief Overview. Acta Histochem. Cytochem. 2020;53:33–42. doi: 10.1267/ahc.20011.
    1. Linsalata M., Riezzo G., D’Attoma B., Clemente C., Orlando A., Russo F. Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-ibs: A case-control study. BMC Gastroenterol. 2018;18:167. doi: 10.1186/s12876-018-0888-6.
    1. Wells J.M., Brummer R.J., Derrien M., MacDonald T.T., Troost F., Cani P.D., Theodorou V., Dekker J., Meheust A., de Vos W.M., et al. Homeostasis of the gut barrier and potential biomarkers. Am. J. Physiol. Gastrointest. Liver Physiol. 2017;312:G171–G193. doi: 10.1152/ajpgi.00048.2015.
    1. Linsalata M., Riezzo G., Clemente C., D’Attoma B., Russo F. Noninvasive biomarkers of gut barrier function in patients suffering from diarrhea predominant-ibs: An update. Dis. Markers. 2020;2020:2886268. doi: 10.1155/2020/2886268.
    1. Camilleri M. Leaky gut: Mechanisms, measurement and clinical implications in humans. Gut. 2019;68:1516–1526. doi: 10.1136/gutjnl-2019-318427.
    1. Fasano A. Zonulin and its regulation of intestinal barrier function: The biological door to inflammation, autoimmunity, and cancer. Physiol. Rev. 2011;91:151–175. doi: 10.1152/physrev.00003.2008.
    1. Pelsers M.M., Hermens W.T., Glatz J.F. Fatty acid-binding proteins as plasma markers of tissue injury. Clin. Chim. Acta. 2005;352:15–35. doi: 10.1016/j.cccn.2004.09.001.
    1. Song W.B., Lv Y.H., Zhang Z.S., Li Y.N., Xiao L.P., Yu X.P., Wang Y.Y., Ji H.L., Ma L. Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease. World J. Gastroenterol. 2009;15:3916–3919. doi: 10.3748/wjg.15.3916.
    1. Zhang L., Fan X., Zhong Z., Xu G., Shen J. Association of plasma diamine oxidase and intestinal fatty acid-binding protein with severity of disease in patient with heat stroke. Am. J. Emerg. Med. 2015;33:867–871. doi: 10.1016/j.ajem.2015.01.047.
    1. Tuck C.J., Reed D.E., Muir J.G., Vanner S.J. Implementation of the low FODMAP diet in functional gastrointestinal symptoms: A real-world experience. Neurogastroenterol. Motil. 2020;32:e13730. doi: 10.1111/nmo.13730.
    1. Orlando A., Tutino V., Notarnicola M., Riezzo G., Linsalata M., Clemente C., Prospero L., Martulli M., D’Attoma B., De Nunzio V., et al. Improved Symptom Profiles and Minimal Inflammation in IBS-D Patients Undergoing a Long-Term Low-FODMAP Diet: A Lipidomic Perspective. Nutrients. 2020;12:1652. doi: 10.3390/nu12061652.
    1. Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395–402. doi: 10.1046/j.1365-2036.1997.142318000.x.
    1. Kulich K.R., Madisch A., Pacini F., Pique J.M., Regula J., Van Rensburg C.J., Ujszaszy L., Carlsson J., Halling K., Wiklund I.K. Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: A six-country study. Health Qual. Life Outcomes. 2008;6:12. doi: 10.1186/1477-7525-6-12.
    1. Schmulson M.J., Drossman D.A. What Is New in Rome IV. J. Neurogastroenterol. Motil. 2017;23:151–163. doi: 10.5056/jnm16214.
    1. Verdu E.F., Armstrong D., Murray J.A. Between celiac disease and irritable bowel syndrome: The “no man’s land” of gluten sensitivity. Am. J. Gastroenterol. 2009;104:1587–1594. doi: 10.1038/ajg.2009.188.
    1. Blake M.R., Raker J.M., Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol. Ther. 2016;44:693–703. doi: 10.1111/apt.13746.
    1. Maagaard L., Ankersen D.V., Vegh Z., Burisch J., Jensen L., Pedersen N., Munkholm P. Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet. World J. Gastroenterol. 2016;22:4009–4019. doi: 10.3748/wjg.v22.i15.4009.
    1. MonashUniversity (2017) The Monash University Low FODMAP App. [(accessed on 4 September 2019)]; Available online:
    1. Linsalata M., D’Attoma B., Orlando A., Guerra V., Russo F. Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in urine of healthy subjects and patients with active celiac disease. Clin. Chem. Lab. Med. 2014;52:e61–e64. doi: 10.1515/cclm-2013-0468.
    1. Hilsden R.J., Meddings J.B., Sutherland L.R. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn’s disease. Gastroenterology. 1996;110:1395–1403. doi: 10.1053/gast.1996.v110.pm8613043.
    1. Simeoni M., Citraro M.L., Cerantonio A., Deodato F., Provenzano M., Cianfrone P., Capria M., Corrado S., Libri E., Comi A., et al. An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD) Eur. J. Nutr. 2019;58:2145–2156. doi: 10.1007/s00394-018-1785-z.
    1. Meeker S., Seamons A., Maggio-Price L., Paik J. Protective links between vitamin D, inflammatory bowel disease and colon cancer. World J. Gastroenterol. 2016;22:933–948. doi: 10.3748/wjg.v22.i3.933.
    1. Barbalho S.M., Goulart R.A., Araujo A.C., Guiguer E.L., Bechara M.D. Irritable bowel syndrome: A review of the general aspects and the potential role of vitamin D. Expert Rev. Gastroenterol. Hepatol. 2019;13:345–359. doi: 10.1080/17474124.2019.1570137.
    1. Eslamian G., Ardehali S.H., Hajimohammadebrahim-Ketabforoush M., Vahdat Shariatpanahi Z. Association of intestinal permeability with admission vitamin D deficiency in patients who are critically ill. J. Investig. Med. 2020;68:397–402. doi: 10.1136/jim-2019-001132.
    1. Kong J., Zhang Z., Musch M.W., Ning G., Sun J., Hart J., Bissonnette M., Li Y.C. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 2008;294:G208–G216. doi: 10.1152/ajpgi.00398.2007.
    1. Zhu T., Liu T.J., Shi Y.Y., Zhao Q. Vitamin D/VDR signaling pathway ameliorates 2,4,6-trinitrobenzene sulfonic acid-induced colitis by inhibiting intestinal epithelial apoptosis. Int. J. Mol. Med. 2015;35:1213–1218. doi: 10.3892/ijmm.2015.2150.
    1. Raftery T., Martineau A.R., Greiller C.L., Ghosh S., McNamara D., Bennett K., Meddings J., O’Sullivan M. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study. United Eur. Gastroenterol. J. 2015;3:294–302. doi: 10.1177/2050640615572176.
    1. McCabe P.S., Pye S.R., Beth J.M., Lee D.M., Tajar A., Bartfai G., Boonen S., Bouillon R., Casanueva F., Finn J.D., et al. Low vitamin D and the risk of developing chronic widespread pain: Results from the European male ageing study. BMC Musculoskelet. Disord. 2016;17:32. doi: 10.1186/s12891-016-0881-6.
    1. Jalili M., Vahedi H., Poustchi H., Hekmatdoost A. Effects of Vitamin D Supplementation in Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Int. J. Prev. Med. 2019;10:16. doi: 10.4103/ijpvm.IJPVM_512_17.
    1. Bicikova M., Duskova M., Vitku J., Kalvachova B., Ripova D., Mohr P., Starka L. Vitamin D in anxiety and affective disorders. Physiol. Res. 2015;64:S101–S103. doi: 10.33549/physiolres.933082.
    1. Ajamian M., Rosella G., Newnham E.D., Biesiekierski J.R., Muir J.G., Gibson P.R. Effect of Gluten Ingestion and FODMAP Restriction on Intestinal Epithelial Integrity in Patients with Irritable Bowel Syndrome and Self-Reported Non-Coeliac Gluten Sensitivity. Mol. Nutr. Food Res. 2020:e1901275. doi: 10.1002/mnfr.201901275.
    1. Zhou S.Y., Gillilland M., III, Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C. FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. J. Clin. Investig. 2018;128:267–280. doi: 10.1172/JCI92390.
    1. Harvie R.M., Chisholm A.W., Bisanz J.E., Burton J.P., Herbison P., Schultz K., Schultz M. Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs. World J. Gastroenterol. 2017;23:4632–4643. doi: 10.3748/wjg.v23.i25.4632.
    1. Gibson P.R., Shepherd S.J. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. J. Gastroenterol. Hepatol. 2010;25:252–258. doi: 10.1111/j.1440-1746.2009.06149.x.
    1. Bascunan K.A., Elli L., Pellegrini N., Scricciolo A., Lombardo V., Doneda L., Vecchi M., Scarpa C., Araya M., Roncoroni L. Impact of FODMAP Content Restrictions on the Quality of Diet for Patients with Celiac Disease on a Gluten-Free Diet. Nutrients. 2019;11:2220. doi: 10.3390/nu11092220.
    1. Vincenzi M., Del Ciondolo I., Pasquini E., Gennai K., Paolini B. Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial. J. Transl. Int. Med. 2017;5:120–126. doi: 10.1515/jtim-2017-0004.
    1. Maes M., Kubera M., Leunis J.C. The gut-brain barrier in major depression: Intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol. Lett. 2008;29:117–124.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere